'Moody' Analysts Upbeat About Quintiles

By Dan Stanton contact

- Last updated on GMT

Related tags: Stock market, Stock

'Moody' Analysts Upbeat About Quintiles
Analysts from rating agency Moody's have upgraded their view of Quintiles, the world’s “largest pharmaceutical service provider,” from stable to positive.

Quintiles rejoined the market it left in 2003 when it went public in May​ after raising more than $1bn (€760m) in its IPO.

Two months on and investment firm Moody’s Investors Services has changed its outlook on Quintiles to positive, citing the firm’s “size, scale and leading position as both a pharmaceutical CRO and a contract sales organization.

“Quintiles, as the largest pharmaceutical service provider, is well-positioned to gain market share and benefit from the industry's growth, the outlook for which is favorable, as pharmaceutical companies look to outsource an increasing portion of their non-core functions.”

Moody’s acknowledged Quintiles - headquartered in Durham, North Carolina – repayment of $350m of debt with proceeds from the IPO, its “significant”​ cash balance and free cash flow expectation of at least $200m per year.

In June a number of other investment analysts gave their verdicts on Quintiles with a mostly positive or neutral outlook​.

Speaking at the time, Tim Evans of Wells Fargo – who gave an outlook of ‘outperform’ and a stock price target of $49 – described Quintiles as “one of the industry’s most disciplined operators”​ predicting the firm “will continue capturing share from small contract research organisations.”

Following the return to the market in May, Quintiles inked a five year exclusive clinical development agreement with Merck-Serono.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Related suppliers

Follow us


View more